Telomere loss in cells treated with cisplatin

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• Telomeres are crucial for cellular immortality and are composed of repetitive DNA sequences.
• The anticancer drug cisplatin targets DNA, forming cross-links that can affect various cellular processes.
• Human telomeres consist of 5'-TTAGGG-3' sequences, which are potential targets for cisplatin-induced damage.

Purpose of the Study:

• To investigate the effect of cisplatin on telomere length and integrity in HeLa cells.
• To elucidate the mechanisms by which cisplatin induces telomere shortening and degradation.
• To develop a model explaining cisplatin-induced telomere loss.

Main Methods:

• Treatment of HeLa cells with varying doses of cisplatin.
• Microscopic observation and analysis of telomere length and degradation.
• Cell cycle progression analysis and apoptosis induction assessment.

Main Results:

• Cisplatin treatment led to marked shortening and degradation of telomeres in HeLa cells.
• Lower cisplatin doses caused telomere shortening before apoptosis induction, even with limited cell division.
• Higher cisplatin doses induced cell cycle arrest in the S phase, followed by apoptosis and telomere degradation.

Conclusions:

• Cisplatin directly impacts telomere structure and length in proliferating cancer cells.
• Both incomplete replication during cell division and cisplatin-induced apoptosis contribute to telomere loss.
• Understanding cisplatin's effect on telomeres provides insights into its anticancer mechanisms and potential side effects.